L-Homoarginine and cardiovascular disease

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 18, Issue 1, 2015, Pages 83-88

  Atzler, Dorothee ^a,b   Schwedhelm, Edzard ^a,b   Choe, Chiun ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Cardiovascular disease; Creatine; L arginine: Glycine amidinotransferase; L homoarginine; Nitric oxide

Indexed keywords

ADENOSINE TRIPHOSPHATE; BIOLOGICAL MARKER; CREATINE; CREATINE PHOSPHATE; GLYCINE AMIDINOTRANSFERASE; HOMOARGININE; NITRIC OXIDE; AMIDINOTRANSFERASE;

AMINO ACID METABOLISM; BRAIN FUNCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; ENERGY METABOLISM; HEART FUNCTION; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; DEFICIENCY; DEVELOPMENTAL DISORDER; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; INTELLECTUAL IMPAIRMENT; METABOLISM; SPEECH DISORDER;

AMIDINOTRANSFERASES; AMINO ACID METABOLISM, INBORN ERRORS; ANIMALS; CARDIOVASCULAR DISEASES; DEVELOPMENTAL DISABILITIES; ENERGY METABOLISM; HOMOARGININE; HUMANS; INTELLECTUAL DISABILITY; SPEECH DISORDERS;

EID: 84916614173     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000123     Document Type: Review

References (34)

1. NicholsM, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: Epidemiological update. Eur Heart J 2014; pii: Ehu299. [Epub ahead of print
2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: A guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 2011; 58: 432-446.
3. März W, Meinitzer A, Drechsler C, et al. Homoarginine, cardiovascular risk, and mortality. Circulation 2010; 122: 967-975.
4. Pilz S, Meinitzer A, Tomaschitz A, et al. Low homoarginine concentration is a novel risk factor for heart disease. Heart 2011; 97: 1222-1227.
5. Choe CU, Atzler D, Wild PS, et al. Homoarginine levels are regulated by L-arginine: Glycine amidinotransferase and affect stroke outcome: Results from human and murine studies. Circulation 2013; 128: 1451-1461.
6. Brosnan JT, da Silva RP, Brosnan ME. The metabolic burden of creatine synthesis. Amino Acids 2011; 40: 1325-1331.
7. Kleber ME, Seppala I, Pilz S, et al. Genome-wide association study identifies 3 genomic loci significantly associated with serum levels of homoarginine: The AtheroRemo Consortium. Circ Cardiovasc Genet 2013; 6: 505-513.
8. Choe CU, Nabuurs C, Stockebrand MC, et al. L-arginine: Glycine amidinotransferase deficiency protects from metabolic syndrome. Hum Mol Genet 2013; 22: 110-123.
9. Nabuurs CI, Choe CU, Veltien A, et al. Disturbed energy metabolism and muscular dystrophy caused by pure creatine deficiency are reversible by creatine intake. J Physiol 2013; 591: 571-592.
10. Davids M, Ndika JD, Salomons GS, et al. Promiscuous activity of arginine: -glycine amidinotransferase is responsible for the synthesis of the novel cardiovascular risk factor homoarginine. FEBS Lett 2012; 586: 3653-3657.
11. Ryan WL, Johnson RJ, Dimari S. Homoarginine synthesis by rat kidney. Arch Biochem Biophys 1969; 131: 521-526.
12. Rao SL. A look at the brighter facets of beta-N-oxalyl-l-alpha, beta-diaminopropionic acid, homoarginine and the grass pea. Food Chem Toxicol 2011; 49: 620-622.
13. Nunn PB, Bell EA, Watson AA, Nash RJ. Toxicity of nonprotein amino acids to humans and domestic animals. Nat Prod Commun 2010; 5: 485-504.
14. Lin CW, Fishman WH. L-Homoarginine. An organ-specific, uncompetitive inhibitor of human liver and bone alkaline phosphohydrolases. J Biol Chem 1972; 247: 3082-3087.
15. Hrabak A, Bajor T, Temesi A. Comparison of substrate and inhibitor specificity of arginase and nitric oxide (NO) synthase for arginine analogues and related compounds in murine and rat macrophages. Biochem Biophys Res Commun 1994; 198: 206-212.
16. Moali C, Boucher JL, Sari MA, et al. Substrate specificity of NO synthases: Detailed comparison of L-arginine, homo-L-arginine, their N omega-hydroxy derivatives, and N omega-hydroxynor-L-arginine. Biochemistry 1998; 37: 10453-10460.
17. Pentyala J, Rao SL. Sustained nitric oxide generation with L-homoarginine. Res Commun Biochem Cell Mol Biol 1999; 3: 223-232.
18. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A 1990; 87: 5193-5197.
19. Reczkowski RS, Ash DE. Rat liver arginase: Kinetic mechanism, alternate substrates, and inhibitors. Arch Biochem Biophys 1994; 312: 31-37.
20. Atzler D, Schwedhelm E, Nauck M, et al. Serum reference intervals of homoarginine, ADMA, and SDMA in the Study of Health in Pomerania. Clin Chem Lab Med 2014; doi: 10.1515/cclm 2014-0314 [Epub ahead of print
21. Pilz S, Teerlink T, Scheffer PG, et al. Homoarginine and mortality in an older population: The Hoorn study. Eur J Clin Invest 2014; 44: 200-208.
22. Drechsler C, Meinitzer A, Pilz S, et al. Homoarginine, heart failure, and sudden cardiac death in haemodialysis patients. Eur J Heart Fail 2011; 13: 852-859.
23. Atzler D, Rosenberg M, Anderssohn M, et al. Homoarginine: An independent marker of mortality in heart failure. Int J Cardiol 2013; 168: 4907-4909.
24. Lygate CA, Schneider JE, Neubauer S. Investigating cardiac energetics in heart failure. Exp Physiol 2013; 98: 601-605.
25. Lygate CA, Bohl S, ten Hove M, et al. Moderate elevation of intracellular creatine by targeting the creatine transporter protects mice from acute myocardial infarction. Cardiovasc Res 2012; 96: 466-475.
26. Phillips D, Ten Hove M, Schneider JE, et al. Mice over-expressing the myocardial creatine transporter develop progressive heart failure and show decreased glycolytic capacity. J Mol Cell Cardiol 2010; 48: 582-590.
27. Lygate CA, Aksentijevic D, Dawson D, et al. Living without creatine: Unchanged exercise capacity and response to chronic myocardial infarction in creatine-deficient mice. Circ Res 2013; 112: 945-955.
28. Ninomiya T. Risk of stroke in kidney disease. Contrib Nephrol 2013; 179: 58-66.
29. Lee M, Saver JL, Chang KH, et al. Low glomerular filtration rate and risk of stroke: Meta-analysis. BMJ 2010; 341: C4249.
30. Brown KE, Dhaun N, Goddard J, Webb DJ. Potential therapeutic role of phosphodiesterase type 5 inhibition in hypertension and chronic kidney disease. Hypertension 2014; 63: 5-11.
31. Ravani P, Maas R, Malberti F, et al. Homoarginine and mortality in predialysis chronic kidney disease (CKD) patients. PLoS One 2013; 8: E72694.
32. Sobczak A, Prokopowicz A, Radek M, et al. Tobacco smoking decreases plasma concentration of the emerging cardiovascular risk marker, L-homoarginine. Circ J 2014; 78: 1254-1258.
33. van der Zwan LP, Davids M, Scheffer PG, et al. L-Homoarginine and L-arginine are antagonistically related to blood pressure in an elderly population: The Hoorn study. J Hypertens 2013; 31: 1114-1123.
34. Kannel WB, Wolf PA. Framingham Study insights on the hazards of elevated blood pressure. JAMA 2008; 300: 2545-2547.